Open house rebate agreements Abatacept, ATC L04AA24
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Abatacept, ATC L04AA24
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No estimated value or volume is provided. The actual business volume under the agreement is unknown and may be very low.
The agreement automatically becomes void if a nationwide or regional rebate contract for the same substance is conclude...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jun 2028
- Non-exclusive rebate agreements for Abatacept (ATC L04AA24) as per § 130a Abs. 8 SGB V
- Standardized contract terms, not individually negotiable
Show full summary
Open-house model for non-exclusive rebate agreements on Abatacept (ATC L04AA24) by AOK Bayern. Any eligible pharmaceutical company can conclude a standard contract without competitive selection. Contract runs from 01 July 2026 to 30 June 2028. Rolling entry with monthly cutoffs; final deadline for contract conclusion is 03 May 2028. No estimated value or volume is provided.
Risks
No estimated value or volume is provided. The actual business volume under the agreement is unknown and may be very low.
The agreement automatically becomes void if a nationwide or regional rebate contract for the same substance is conclude...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Contract and annex must be signed by an authorized representative (proof of authority required via commercial register extract or power of attorney)
Eligibility
- Only pharmaceutical companies are eligible to participate
Administrative
- Must submit a signed declaration of reliability
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house rebate agreements Abatacept, ATC L04AA24
Non-exclusive rebate agreement for the active substance Abatacept. The contract is a standard, non-negotiable agreement offered to all interested pharmaceutical companies meeting eligibility criteria. The contract can be terminated with one month's notice. It automatically becomes void if a nationwide or region-specific rebate contract for the same substance is concluded via an open procedure.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Abatacept, ATC L04AA24
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 17 May 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 336029-2026
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No estimated value or volume is provided. The actual business volume under the agreement is unknown and may be very low.
The agreement automatically becomes void if a nationwide or regional rebate contract for the same substance is conclude...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications